Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.
Phase 2
Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Drug: Doxycline
- First Posted Date
- 2007-09-19
- Last Posted Date
- 2015-02-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 147
- Registration Number
- NCT00531934
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
Phase 3
Completed
- Conditions
- Breast Cancer
- Interventions
- Drug: Standard adjuvant chemotherapy
- First Posted Date
- 2007-09-12
- Last Posted Date
- 2015-09-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2591
- Registration Number
- NCT00528567
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.
Phase 2
Completed
- Conditions
- Renal Cell Cancer
- Interventions
- First Posted Date
- 2007-08-24
- Last Posted Date
- 2014-10-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 25
- Registration Number
- NCT00520403
A Prospective Study to Assess the Screening Value of N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) for the Identification of Patients That Benefit From Additional Cardiac Testing Prior to Vascular Surgery
Not Applicable
- Conditions
- Peripheral Vascular Disease
- Interventions
- Device: Elecsys®proBNP
- First Posted Date
- 2007-08-23
- Last Posted Date
- 2011-03-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1800
- Registration Number
- NCT00519961
A Prospective Study to Evaluate the Specificity of the Cobas TaqScreen MPX Test for Use on the Cobas s 201 System for Screening Plasma Pools From Source Plasma Donors for the Presence of HBV DNA, HCV RNA, and HIV-1 RNA
Not Applicable
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Device: cobas s 201 TaqScreen MPX Test
- First Posted Date
- 2007-08-23
- Last Posted Date
- 2016-03-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 100000
- Registration Number
- NCT00520273
LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
Phase 3
Completed
- Conditions
- Anemia
- Interventions
- Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
- First Posted Date
- 2007-08-17
- Last Posted Date
- 2016-04-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 163
- Registration Number
- NCT00517413
A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.
Phase 2
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2007-08-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 516
- Registration Number
- NCT00517439
Efficacy, Safety and Tolerability Study of Subcutaneous C.E.R.A. in Pre-Dialysis Participants With Chronic Renal Anemia
Phase 3
Terminated
- Conditions
- Anemia
- Interventions
- Drug: Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)
- First Posted Date
- 2007-08-17
- Last Posted Date
- 2016-05-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 29
- Registration Number
- NCT00517881
A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus.
- First Posted Date
- 2007-08-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 41
- Registration Number
- NCT00517465
A Single Ascending Dose Study of R1671 in Patients With Mild Intermittent Asymptomatic Asthma.
- First Posted Date
- 2007-08-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 43
- Registration Number
- NCT00517816
© Copyright 2025. All Rights Reserved by MedPath